Our Company | Fortis Life Sciences
OUR COMPANY

One Force
Forward

Scientific progress depends on the expertise,
reagents and technologies behind every experiment.

Contact Us
We are Fortis Life Sciences

Where science
finds
momentum.

Fortis was established in 2020 to create a more unified and scalable approach to supporting modern research and development.

7Global brands united
6North American manufacturing and R&D sites
30,000+Citations in publications

Together, Fortis companies provide capabilities across

antibodiesdiagnostic componentsviral vector platformsmolecular biology reagentsengineered nanoparticleslyophilizationmanufacturing

so you can work with greater continuity across complex scientific workflows.

1,100+Customers globally
75+Distributors serving customers

Work that once required multiple suppliers can now move forward with one partner. The result is stronger technical alignment, a more stable supply chain, and support across discovery, translational research, and advanced biologics development.

See What’s New at Fortis
Fortis
Discovery

Bethyl
Laboratories

Acquired by Fortis 2020
For more than fifty years, Bethyl Laboratories has manufactured antibodies, proteins, and immunoassay kits in-house in Montgomery, Texas, tested for specificity and reproducibility across such as: flow cytometry, spatial biology, and ELISA platforms.Founded 1972
Advanced Discovery

Abcore

Acquired by Fortis 2022
Abcore's VHH single-domain antibody discovery, built on phage display screening, addresses difficult and emerging targets across research, therapeutic, and diagnostic programs.Founded 2011
Diagnostic Components

Arista Biologicals

Acquired by Fortis 2021
Arista Biologicals supplies highly characterized antibodies, antigens, and controls purpose-built for point-of-care and lateral flow diagnostics, backed by conjugation and assay development expertise across infectious disease, fertility, and toxicology testing.Founded 1993
Functional Validation

Vector Biolabs

Acquired by Fortis 2023
Once a target is identified, researchers need to confirm what happens when a gene is activated, silenced, or delivered into a living system. Vector Biolabs' catalog and custom AAV and adenoviral vector design and production supply that functional step, moving a hypothesis toward a therapeutic candidate.Founded 2004
Precision Engineering

nanoComposix

Acquired by Fortis 2021
As diagnostics and therapeutics moved toward smaller, more targeted mechanisms, nanoComposix added the materials science to match: engineered nanoparticles characterized for targeted delivery and enhanced diagnostic signal.Founded 2004
Molecular Production

Empirical
Bioscience

Acquired by Fortis 2021
Antibody and nanoparticle development both depend on the molecular biology tools underneath them: enzymes, master mixes, and recombinant proteins. Empirical Bioscience has that capability at production scale, supporting genomic and diagnostic workflows beyond what a single research lab can produce in-house.Founded 2010
Production & Global Reach

IPOC

Acquired by Fortis 2023
IPOC's lyophilization expertise stabilizes molecular and immunodiagnostic reagents for global distribution, extending Fortis' reach to labs and patients well beyond the range of a cold chain.Founded 2008

Harness
the Power of Many

Proven Expertise

Decades of hands-on experience across antibody development, molecular biology, and nanoparticle engineering help you move from a difficult target to a validated result.

Contact Us

Custom Services

With our custom antibody development, VHH and phage display discovery, conjugate and assay optimization, and bulk or OEM production, the complex steps of your workflow go to specialists who have solved them before.

Our Services

Premium Portfolio

Advance your programs with products developed, validated, and continually expanded in-house, backed by our Farm-to-Bench production model and rigorous quality controls.

Our Products

Customer-validated
performance

We’ve been consistently pleased by Bethyl’s

initial candidate
success rate.

They are creative in their workflows, responsive to our inputs, and a great group to work with overall. We're now engaged in multiple projects, with multiple anti-PTM clones about to be launched as formal genomic mapping reagents.
Michael-Christopher Keogh, PhD
Chief Scientific Officer, EpiCypher Inc.
Michael-Christopher Keogh, PhD
ONE

Fortis trusted brands stand shoulder to shoulder, to accelerate the future of scientific progress.

Meet the Fortis Team